Novo Nordisk develops new mechanical insulin pill with star researchers from MIT

Novo Nordisk has developed a new pill technology, the future basis for an insulin pill, in collaboration with star researcher Robert Langer and his team at MIT. The company expects clinical studies to take place in two to three years.
The new pill technology Lumi consists of a three-pointed needle construction, that is shot into the small intestine by a spring and injects insuline into the intestine wall. | Photo: MIT/ PR
The new pill technology Lumi consists of a three-pointed needle construction, that is shot into the small intestine by a spring and injects insuline into the intestine wall. | Photo: MIT/ PR
BY KEVIN GRØNNEMANN

It was to the “deep frustration” of research director Mads Krogsgaard Thomsen that Novo Nordisk gave up on a year long project to develop an insulin pill, that would have given type 1 diabetics a needle-free alternative, in 2016.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading